BENZENEACETICACID,4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL- Cas:202189-78-4

We are BENZENEACETICACID,4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL- CAS:202189-78-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description:

Product Name:

BENZENEACETICACID,4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL)-1-PIPERIDINYL)ETHYL-ALPHA, ALPHA-DIMETHYL- CAS NO: 202189-78-4

 

Synonyms:             

2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic acid;

4-[2-[4-[1-(2-Ethoxyethyl)-1H-benziMidazol-2-yl]-1-piperidinyl]ethyl]-α,α-diMethylbenzeneacetic Acid;

Benzeneaceticacid,4-[2-[4-[1-(2-ethoxyethyl)-1H-benziMidazol-2-yl]-1-piperidinyl]ethyl]-a,a-diMethyl-;

 

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.0%

Density: 1.16g/cm3

Boiling Point: 639.1℃ at 760mmHg

Flash Point: 340.3℃

Refractive Index: 1.594

Vapor Pressure: 3.29E-17mmHg at 25℃

 

Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).

It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.

Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.

Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:Benzenediazonium, 2-carboxy-4,5-difluoro-, chloride manufacturer | 1-((E)-2-Benzyl-4-methylsulfanyl-1-phenyl-but-3-ene-2-sulfonyl)-4-methyl-benzene supplier | Glycine, N2-(6-amino-1-oxohexyl)-L-arginyl-L-seryl-L-arginyl- producer.